Nivolumab plus chimiothérapie dans le cancer gastrique métastatique Nivolumab plus chemotherapy in advanced gastric cancer Janjigian YY, Shitara K, Moehler M, et al. First-line nivolumab plus chemotherapy [...]
Réf. Convergences.online/Onco ; 1(1) : R12 Kelly RJ, Ajani JA, Kuzdzal J, et al. Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer. N Engl J Med. 2021 Apr 1;384(13):1191-1203. [...]
Sintilimab plus platinum and gemcitabine as first-line treatment for advanced or metastatic squamous non-small-cell lung cancer: results from a randomized, double-blind, phase 3 trial (ORIENT-12). Zhou et al. J Thorac Oncol. 2021 [...]
Epigenetic regulation of angiogenesis in lung cancer. Tan et al. J Cell Physiol. 2021 May;236(5):3194-3206.
Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials. Theelen and al. J Cell Physiol. 2021 May;236(5):3194-3206.
Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities. Gay and al. Lancet Respir Med. 2021 May;9(5):467-475.
Convergences.online/Onco ; 1 (1) : U4 Résultats actualisés de l’essai Checkmate 9LA évaluant l’association nivolumab + ipilimumab + 2 cycles initiaux de chimiothérapie, suivis d’une maintenance par la double immunothérapie versus la [...]
Réf. : Convergences.online/Onco ; 1 (1) : R11 Makoto Nishio et al. Atezolizumab Plus Chemotherapy for First-Line Treatment of Nonsquamous NSCLC: Results From the Randomized Phase 3 IMpower132 Trial. J Thorac Oncol.2021 Apr;16(4):653-664. [...]
Réf. : Convergences.online/Onco ; 1 (1) : R10 Dean A Fennell et al. Lancet Respir Med. 2021 Jan 27;S2213-2600(20)30390-8. Rucaparib in patients with BAP1-deficient or BRCA1-deficient mesothelioma (MiST1): an open-label, single-arm, phase [...]
Réf. : Convergences.online/Onco ; 1 (1) : R9 Ahmet Sezeret al. Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase [...]
